C14orf166 is a high-risk biomarker for bladder cancer and promotes bladder cancer cell proliferation.
PubWeight™: 0.75‹?›
Published in J Transl Med on February 23, 2016
Authors
Mingkun Chen1,2, Yunlin Ye3,4, Baojia Zou5,6, Suping Guo7, Fangjian Zhou8,9, Keshi Lu10, Jianye Liu11, Zhenzhou Xu12, Hui Han13,14, Zhuowei Liu15,16, Yonghong Li17,18, Kai Yao19,20, Cundong Liu21, Zike Qin22,23
Author Affiliations
1: State Key Laboratory of Oncology in South China, 510060, Guangzhou, Guangdong, People's Republic of China. mingkun07@163.com.
2: Department of Urology, The Third Affiliated Hospital of Southern Medical University, 510630, Guangzhou, Guangdong, People's Republic of China. mingkun07@163.com.
3: State Key Laboratory of Oncology in South China, 510060, Guangzhou, Guangdong, People's Republic of China. yeyunl@sysucc.org.cn.
4: Department of Urology, Cancer Center, Sun Yat-sen University, 510060, Guangzhou, Guangdong, People's Republic of China. yeyunl@sysucc.org.cn.
5: State Key Laboratory of Oncology in South China, 510060, Guangzhou, Guangdong, People's Republic of China. joseph.b.zou@gmail.com.
6: Department of Urology, Cancer Center, Sun Yat-sen University, 510060, Guangzhou, Guangdong, People's Republic of China. joseph.b.zou@gmail.com.
7: Department of Radiotherapy, Cancer Center, Sun Yat-sen University, 510060, Guangzhou, Guangdong, People's Republic of China. 2275531816@qq.com.
8: State Key Laboratory of Oncology in South China, 510060, Guangzhou, Guangdong, People's Republic of China. 351844459@qq.com.
9: Department of Urology, Cancer Center, Sun Yat-sen University, 510060, Guangzhou, Guangdong, People's Republic of China. 351844459@qq.com.
10: Department of Urology, Shenzhen Children's Hospital, 518026, Shenzhen, Guangdong, People's Republic of China. 17673971@qq.com.
11: Department of Urology, The Third Xiangya Hospital of Central South University, 410000, Changhsa, Hunan, People's Republic of China. 410849661@qq.com.
12: Department of Urology, Hunan Cancer Hospital, 410000, Changsha, Hunan, People's Republic of China. xzzeva@163.com.
13: State Key Laboratory of Oncology in South China, 510060, Guangzhou, Guangdong, People's Republic of China. mingkun01@163.com.
14: Department of Urology, Cancer Center, Sun Yat-sen University, 510060, Guangzhou, Guangdong, People's Republic of China. mingkun01@163.com.
15: State Key Laboratory of Oncology in South China, 510060, Guangzhou, Guangdong, People's Republic of China. Victormoney@sina.com.
16: Department of Urology, Cancer Center, Sun Yat-sen University, 510060, Guangzhou, Guangdong, People's Republic of China. Victormoney@sina.com.
17: State Key Laboratory of Oncology in South China, 510060, Guangzhou, Guangdong, People's Republic of China. 807211316@qq.com.
18: Department of Urology, Cancer Center, Sun Yat-sen University, 510060, Guangzhou, Guangdong, People's Republic of China. 807211316@qq.com.
19: State Key Laboratory of Oncology in South China, 510060, Guangzhou, Guangdong, People's Republic of China. yaokai2015@sohu.com.
20: Department of Urology, Cancer Center, Sun Yat-sen University, 510060, Guangzhou, Guangdong, People's Republic of China. yaokai2015@sohu.com.
21: Department of Urology, The Third Affiliated Hospital of Southern Medical University, 510630, Guangzhou, Guangdong, People's Republic of China. chen_mk@sina.com.
22: State Key Laboratory of Oncology in South China, 510060, Guangzhou, Guangdong, People's Republic of China. qinzk@sysucc.org.cn.
23: Department of Urology, Cancer Center, Sun Yat-sen University, 510060, Guangzhou, Guangdong, People's Republic of China. qinzk@sysucc.org.cn.
Articles cited by this ↗
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16
The RB and p53 pathways in cancer. Cancer Cell (2002) 8.02
The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer (2008) 6.22
p21-activated kinases in cancer. Nat Rev Cancer (2006) 4.24
Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov (2009) 4.16
A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat Genet (2010) 2.56
Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer (2015) 2.47
Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet (2006) 2.22
PA subunit from influenza virus polymerase complex interacts with a cellular protein with homology to a family of transcriptional activators. J Virol (2001) 1.98
Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer. Mol Cancer (2011) 1.75
Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat Rev Urol (2014) 1.19
Overexpression of the wild type p73 gene in human bladder cancer. Oncogene (1999) 1.18
Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy in bladder cancer: ready for prime time? J Clin Oncol (2014) 1.13
Neoadjuvant phase II studies of modified methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer. J Clin Oncol (2014) 1.09
Involvement of upregulation of DEPDC1 (DEP domain containing 1) in bladder carcinogenesis. Oncogene (2007) 1.07
Proteomic profiling in pancreatic cancer with and without lymph node metastasis. Int J Cancer (2009) 1.03
FOXO transcription factor-dependent p15(INK4b) and p19(INK4d) expression. Oncogene (2007) 1.02
Identification of hnRNPH1, NF45, and C14orf166 as novel host interacting partners of the mature hepatitis C virus core protein. J Proteome Res (2011) 0.95
Oncogenic role of MPHOSPH1, a cancer-testis antigen specific to human bladder cancer. Cancer Res (2007) 0.95
Biomarkers for bladder cancer management: present and future. Am J Clin Exp Urol (2014) 0.95
Acylglycerol kinase augments JAK2/STAT3 signaling in esophageal squamous cells. J Clin Invest (2013) 0.94
Combination of AG490, a Jak2 inhibitor, and methylsulfonylmethane synergistically suppresses bladder tumor growth via the Jak2/STAT3 pathway. Int J Oncol (2014) 0.91
Cellular human CLE/C14orf166 protein interacts with influenza virus polymerase and is required for viral replication. J Virol (2011) 0.89
A novel ninein-interaction protein, CGI-99, blocks ninein phosphorylation by GSK3beta and is highly expressed in brain tumors. FEBS Lett (2004) 0.89
Chromosome 4p16.3 variant modify bladder cancer risk in a Chinese population. Carcinogenesis (2011) 0.86
Overexpression of chromosome 14 open reading frame 166 correlates with disease progression and poorer prognosis in human NPC. Tumour Biol (2015) 0.81
Interaction of PTPIP51 with Tubulin, CGI-99 and Nuf2 During Cell Cycle Progression. Biomolecules (2012) 0.80
C14ORF166 overexpression is associated with pelvic lymph node metastasis and poor prognosis in uterine cervical cancer. Tumour Biol (2015) 0.80